Medication info
Il Yang Losartan Plus Tablet

Il Yang Losartan Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Il Yang Pharmaceutical Co., Ltd.
Appearance
White to grayish-white oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200906584 · Notified 2009.08.27 · Insurance code 641703510

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not desirable. In general, the maximum blood pressure-lowering effect is seen approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken regardless of meals. To minimize adverse reactions, initiate this medicine when the expected effect has not been achieved with monotherapy. 1. Replacement therapy : The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose : Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which reduces the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Administration is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium for these patients, 25 mg, cannot be administered using this medicine.
Child dose
Children (under 18 years): As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Il Yang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension whose blood pressure is not adequately controlled with monotherapy. It helps to lower blood pressure effectively and reduce the risk of cardiovascular disease when this medication is added to treatment that is insufficient on its own.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not desirable. In general, the maximum blood pressure-lowering effect is seen approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken regardless of meals. To minimize adverse reactions, initiate this medicine when the expected effect has not been achieved with monotherapy. 1. Replacement therapy : The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose : Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which reduces the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of administration, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Administration is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium for these patients, 25 mg, cannot be administered using this medicine.

Child dose

Children (under 18 years): As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus when taken during pregnancy, so discontinue immediately if pregnancy is confirmed. Patients who are allergic to this medication or have severely impaired kidney function, as well as those with certain electrolyte imbalances, should not take it. Patients with low blood pressure, kidney disorders, or liver disorders should use this medication cautiously, especially elderly patients or those with diabetes. Regular monitoring of blood pressure, kidney function, and electrolyte levels is necessary while taking this medication to ensure there are no abnormalities. This medication can affect blood potassium levels, so avoid taking it with potassium supplements or drugs containing potassium. Hydrochlorothiazide can cause side effects like electrolyte imbalance, hypokalemia, and hyponatremia, so consult a doctor immediately if symptoms occur. Dizziness or drowsiness may occur while taking this medication, so exercise caution when driving or operating machinery. Hydrochlorothiazide can increase sensitivity to sunlight and raise the risk of skin cancer, so sun exposure should be limited and protective measures taken. In case of overdose, symptoms like low blood pressure or arrhythmias may occur, so adhere to the prescribed dosage and visit a medical facility immediately if unusual symptoms arise. This medication is not recommended for children and adolescents, and breastfeeding women should consult a doctor before taking it. Regular blood tests and health status check-ups as advised by a doctor are necessary before and after taking this medication.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
Show 127 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin peeling phenomenon
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • lower limb pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • irritability
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • respiratory distress
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus dysfunction
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • phototoxic reactions
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • diminished vision
  • taste disturbances
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequency of urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a container that blocks light and air, ideally at room temperature between 1 and 30 degrees Celsius. This way of storage helps maintain the efficacy of the medication.

Appearance and packaging

Appearance

White to grayish-white oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.